Aggregation of features of the metabolic syndrome is associated with increased prevalence of chronic complications in Type 2 diabetes

Costa, Luiz Francisco Machado da; Canani, Luís Henrique Santos; Lisboa, Hugo Roberto Kurtz; Três, Gláucia Sarturi; Gross, Jorge Luiz

doi:10.1111/j.1464-5491.2004.01124.x

Cited by 168 publications

(124 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, the increase in the number of components of metabolic syndrome in patients with central obesity was associated with an increase in carotid IMT. These findings are consistent with the report revealing that the aggregation of features of metabolic syndrome is associated with increased CVD in type 2 diabetes [16,31], and suggested that central obesity is associated with the development of atherosclerosis via several atherosclerotic risk factors.…”

Section: Discussionsupporting

confidence: 82%

“…This is consistent with reports revealing that the combination of high waist circumference value and high triglyceride level is a better predictor of CVD than either alone [30]. Our study revealed that 93.3% (men 94.5%, women 89.7%) of patients with central obesity had hypertension and/or dyslipidemia shown in Table 2, and this ratio was similar with that in a previous study for 1,424 Japanese type 2 diabetic patients and higher than that for general populations [1][2][3]31]. These findings represent specific features in metabolic syndrome in type 2 diabetic patients; that is, most of type 2 diabetic patients with central obesity have hypertension and/or dyslipidemia and is logically diagnosed metabolic syndrome.…”

Section: Discussionsupporting

confidence: 82%

See 1 more Smart Citation

Is Central Obesity a Good Predictor of Carotid Atherosclerosis in Japanese Type 2 Diabetes with Metabolic Syndrome?

et al. 2007

View full text Add to dashboard Cite

Abstract. Metabolic syndrome has been revealed to be a major risk factor for cardiovascular disease (CVD) and early mortality in non-diabetic and diabetic patients. In 2005, the International Diabetes Federation (IDF) and the Examination Committee of Criteria for Diagnosis of Metabolic Syndrome in Japan published new definitions of metabolic syndrome in which central obesity was an indispensable factor. However, the significance of this new definition to CVD in type 2 diabetes has not yet been clarified. A cross-sectional study was conducted with 294 Japanese type 2 diabetic patients without known cardiovascular disease to evaluate the association between metabolic syndrome defined by this new definition and carotid atherosclerosis, and the significance of central obesity for the prediction of the development of carotid atherosclerosis. In a multivariate regression analysis, metabolic syndrome but not central obesity was significantly associated with carotid intima-media thickness (IMT) independent of known cardiovascular risk factors (p<0.05). In addition, whereas carotid IMT was significantly increased according to the increase in the number of components of metabolic syndrome, it was not significantly different between the groups with the same number of components of metabolic syndrome with or without central obesity. These findings suggest that the prediction of the development of carotid atherosclerosis in Japanese type 2 diabetic patients could be improved by the assessment of aggregation of components of metabolic syndrome rather than with or without metabolic syndrome by this new definition.

show abstract

Section: Discussionsupporting

confidence: 82%

Section: Discussionsupporting

confidence: 82%

Is Central Obesity a Good Predictor of Carotid Atherosclerosis in Japanese Type 2 Diabetes with Metabolic Syndrome?

et al. 2007

View full text Add to dashboard Cite

show abstract

“…Multiple studies have implicated the metabolic syndrome (MetS) as a potential cause of peripheral neuropathy 11, 12, 13, 14. However, studies that have investigated the contributions of the individual components have revealed mixed results 15, 16, 17, 18, 19, 20, 21.…”

Section: Introductionmentioning

confidence: 99%

Diabetes and obesity are the main metabolic drivers of peripheral neuropathy

Callaghan

Gao

Li³

et al. 2018

Ann Clin Transl Neurol

147

110

View full text Add to dashboard Cite

ObjectiveTo determine the associations between individual metabolic syndrome (MetS) components and peripheral neuropathy in a large population‐based cohort from Pinggu, China.MethodsA cross‐sectional, randomly selected, population‐based survey of participants from Pinggu, China was performed. Metabolic phenotyping and neuropathy outcomes were performed by trained personnel. Glycemic status was defined according to the American Diabetes Association criteria, and the MetS using modified consensus criteria (body mass index instead of waist circumference). The primary peripheral neuropathy outcome was the Michigan Neuropathy Screening Instrument (MNSI) examination. Secondary outcomes were the MNSI questionnaire and monofilament testing. Multivariable models were used to assess for associations between individual MetS components and peripheral neuropathy. Tree‐based methods were used to construct a classifier for peripheral neuropathy using demographics and MetS components.ResultsThe mean (SD) age of the 4002 participants was 51.6 (11.8) and 51.0% were male; 37.2% of the population had normoglycemia, 44.0% prediabetes, and 18.9% diabetes. The prevalence of peripheral neuropathy increased with worsening glycemic status (3.25% in normoglycemia, 6.29% in prediabetes, and 15.12% in diabetes, P < 0.0001). Diabetes (odds ratio [OR] 2.60, 95% CI 1.77–3.80) and weight (OR 1.09, 95% CI 1.02–1.18) were significantly associated with peripheral neuropathy. Age, diabetes, and weight were the primary splitters in the classification tree for peripheral neuropathy.InterpretationSimilar to previous studies, diabetes and obesity are the main metabolic drivers of peripheral neuropathy. The consistency of these results reinforces the urgent need for effective interventions that target these metabolic factors to prevent and/or treat peripheral neuropathy.

show abstract

“…A nefropatia diabética acomete mais de um terço dos pacientes e é a causa mais comum de doença renal terminal e ingresso em programas de hemodiálise (1), e a retinopatia diabética é a principal causa de cegueira entre os 20-74 anos. As doenças cardiovasculares (DCV) são responsáveis por mais de 50% das mortes em pacientes com DM tipo 2 (DM2) e também por 30% das internações em centros de tratamento intensivo (2).…”

Section: Introductionunclassified

Glico-hemoglobina (HbA1c): aspectos clínicos e analíticos

Camargo

Gross

2004

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

RESUMOA glico-hemoglobina (GHb) é um parâmetro importante no controle glicêmico de pacientes com DM. Vários estudos clínicos mostraram claramente que a melhora no controle glicêmico está fortemente associada com a diminuição no desenvolvimento e/ou progressão das complicações em diabetes melito tipos 1 e 2. A medida exata e precisa da GHb é uma questão importante para os laboratórios clínicos. Vários fatores afetam os resultados e podem levar a resultados errôneos. Nesta revisão, discutimos os problemas da padronização da determinação da GHb para monitorar a terapia diabética e também os principais fatores interferentes. Os métodos para GHb podem ser diferentemente afetados pelas interferências. O efeito da interferência pode ser clinicamente mais relevante com o pior controle glicêmico. O laboratório deve estar atento para estes fatores para evitar confusão na interpretação clínica dos resultados, e os clínicos devem contatar o laboratório sempre que houver discrepância entre a impressão clínica e o resultado laboratorial. Glycohemoglobin (GHb) has a key role in the assessment of glycemic control in diabetic patients. Several studies have clearly shown that improved glycemic control is strongly associated with decreased development and/or progression of diabetic complications in both type 1 and 2 diabetes mellitus. Therefore, accurate determination of GHb concentration is an important issue for clinical laboratories. Several factors may affect and lead to erroneous results. We discuss the problems of standardization of GHb measurements for monitoring glycemic control and also consider the potential interfering factors on GHb measurements. Moreover, GHb assays may be affected by interference in different ways. The effect of interference may be more clinically relevant with poor metabolic control. Laboratory staff must be aware of all pitfalls to avoid adding more confusion to the clinical interpretation of HbA 1c values and physicians should contact laboratories if discrepancies between clinical impressions and laboratory data are observed.

show abstract

Aggregation of features of the metabolic syndrome is associated with increased prevalence of chronic complications in Type 2 diabetes

Abstract: The metabolic syndrome and the aggregation of its components were significantly associated with macro- and microvascular complications in Type 2 DM patients.

Cited by 168 publications

References 19 publications

Is Central Obesity a Good Predictor of Carotid Atherosclerosis in Japanese Type 2 Diabetes with Metabolic Syndrome?

Is Central Obesity a Good Predictor of Carotid Atherosclerosis in Japanese Type 2 Diabetes with Metabolic Syndrome?

Diabetes and obesity are the main metabolic drivers of peripheral neuropathy

Glico-hemoglobina (HbA1c): aspectos clínicos e analíticos

Contact Info

Product

Resources

About